Eli Lilly & Co. (LLY)

Strong sales of its newer products will keep them going strong.

Pharaceuticals will suffer under this administration's plan for universal care

Use to work there...anemic, in-bred culture...stock has done nothing in last 7 years, xyprexa off patent in 2010. Despite calls they have one of the best pipelines, stock sucks and is fairly if not over valued.

Big Pharma is going to have some serious issues ahead. LLY is small enough to be a target for Pfizer or J&J. LLY also has a decent amount of biotech business to make them attractive.

Given that the general market is going to crash, LLY's stable income should help the stock beat the market.

Low PE, decent Yield and time to start doing better.

I've been waiting for this one. It's time to BUY.

We need to add the dividend re-investment function to CAPS for slower growing stocks like this one.

Growing? Yeah. LLY has just about shaken the disease of traveling downward and sideways.

Going up from here...

Chosen to be a part of the High Yield Portfolio strategy. Originally created by Fool UK's Stephen Bland (TMFPyad) in November 2000, the High-Yield Portfolio (HYP) strategy invests in a diversified group of 15 blue chip dividend-paying stocks with strong dividend cover, relatively low debt, and a history of increasing dividend payouts. The holding period is theoretically forever -- unless a stock is bought out or cuts its dividend.

Sound crazy? Well, the point of the portfolio is not necessarily for capital gains (although that's certainly a bonus), but to produce increasing amounts of annual dividend income. Daily price fluctuations matter not -- it's the income that matters -- so it removes emotional trading from the picture entirely. Doubters should note that the original UK HYP from November 2000 returned 68% through December 2007 (while the FTSE 100 lost 8%). What's more, the portfolio income payout increased 29% over that seven year period, from 3,451 pounds to 4,462 pounds per year.

Off label promotion of certain drugs leaves me to think the overall nature of this company is fundamentally flawed.

class action lawsuit will offset quartly gains probably settle out of court so loss to company will remain unknown

no new products

Good track record and pipeline seems strong

Diabetic drug company should benefit from the increase in diabetes in the U.S (and God willing one day they will discover a cure).

Cymbalta will do better than expected

Yes, I know Cramer thinks LLY is a great rebalancing play. By now, the whole world knows so who knows if this'll really happen. I hope so, but regardless, I'm holding LLY for the long-term. They do have a great pipeline and I view the oppty arguably better than a few others that have had a nice run. I really like AZN (which is up 30%+ this year) but don't know how many more legs it has. So, while I'm not selling my AZN yet, I'm buying into LLY for upside in 2007.

One of the biggest drug companies in the world. They have several big drugs, and are always have more in the pipeline. They may not have explosive growth all the time, but when they hit on something new they will jump. They have the resources to spend on the development that is crucial for any pharma to have. They also pay one of the larger pharma dividends to tide you through the slow times.

STABILLITY

Good health play, strong history of growth

Aging/dividend

I own some, so of course I want it to do well.